Loading stock data…
Viridian Therapeutics, Inc. (VRDN)
$19.27+0.01 (+0.05%)
Market ClosedLast close Jul 24
Viridian Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Viridian Therapeutics, Inc. in the Healthcare sector is trading at $19.27 with a market capitalization of $1.8B. Wall Street consensus targets $36.12 (16 analysts), implying a +87.5% move over the next 12 months. The stock is currently 44% below its 52-week high of $34.29, remaining 19.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +87.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $141,000↑ | $132,000↓ | $70.57M↑ | $75,000↑ | $72,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$116.17M↑ | -$122.75M↓ | -$40.01M↑ | -$106.77M↓ | -$93.87M |
| Net Income | -$104.90M↑ | -$120.36M↓ | -$34.60M↑ | -$100.73M↓ | -$86.91M |
Peer Comparison
JNJUNHPFE
Fundamentals
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclona...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.81B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-56.70%
Volume
Today's trading volume
1.52M
Recent News
Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 affordable biotech stocks to buy right now. On June 30, Goldman Sachs increased its target price for Viridian Therapeutics Inc. (NASDAQ:VRDN) from $35 to $39, implying an adjusted upside potential in excess of 105% at the prevailing level. The firm maintained its Buy rating on the […]
Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich?
Viridian Therapeutics (VRDN) has drawn fresh investor attention after recent trading left the stock at $19.08. Recent performance has been mixed across different periods, and the company’s business remains focused on therapies for serious and rare diseases. See our latest analysis for Viridian Therapeutics. At a share price of $19.08, Viridian Therapeutics reflects a mixed picture, with a 30 day share price return of 16.70% and a 90 day share price return of 28.23%, alongside a year to date...
Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today
Viridian Therapeutics stock has fallen 37.8% year to date, yet the valuation checks still point to the shares looking expensive rather than like a clear bargain. The year to date decline of 37.8% raises the question of whether the recent weakness has gone far enough to justify the current share price. Future revenue potential from Viridian Therapeutics' pipeline can support higher expectations, but the need to fund ongoing development and potential cash burn may weigh on what investors are...
“Stay Invested”: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market
What to make of the markets today? The biggest story in recent months has been the conflict in the Middle East and its effect on oil prices. After pulling back for a while, crude has started moving higher again as geopolitical tensions raise concerns about potential supply disruptions. Meanwhile, the Federal Reserve left interest rates unchanged at its latest meeting. Although inflation has continued to cool overall, the recent move in oil reminds investors that geopolitical developments can sti
Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone
With EPS growth for the next five years forecasted at 67.57%, Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 12 Best Quality Stocks to Buy and Hold for the Next Decade. On June 30, Wedbush analyst Laura Chico raised the firm’s price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $43 from $32 while maintaining an Outperform rating following […]